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1. INTRODUCTION 
Medicines are medical products subject to state 
intervention in all their phases (1), being multi-
dimensional products (2). According to Valverde (3): 
“there must be a need of moving towards a free global 
movement of medicines taking into account the specific 
problems of developing countries”. The legal regulation of 
medicines can not be understood without a detailed 
regulation of persons, both natural and legal persons 
involved in the circulation and supply of medicines (4). 
Nowadays, worldwide, there is an irregular supply of 
medicines. This activity is a great threat that has to be 
controlled by the public administration as guarantor of 
citizens' rights. 
We should understand that the movement of counterfeit 
medicines is an emerging problem in both developed and 
developing countries. Although in Spain the distribution 
chain is secure, health authorities should be alert to the 
emergence of possible counterfeit medicines, especially 
sold online through websites. The community pharmacist 
occupies the best position to exercise pharmacovigilance 
and detection activities of counterfeit medicines since at 
present there is a large number of consumption in 
developed countries due to the population's feeling of 
insecurity. 
Although health authorities in developed countries had 
proved the existence of spurious/falsely-labelled/falsified/ 
and counterfeit medicines, they thought they could only be 
purchased by users via Internet. There was no evidence 
that might be found in legal distribution channels, at least 
in the European Union. 
However, in 2007, the British health authorities 
detected more than two million doses of Zyprexa 
imported, nearly half of them were acquired by patients. 
This medicine did not contain the doses indicated in its 
fact sheet (5). 
For this reason, and given the health alert that occurred, 
it was decided to regulate/change urgently issues related to 
distribution and import of medicines in the European 
Union in order to ensure proper distribution channel of the 
medicines 
2. SITUATION OF COUNTERFEIT MEDICINES IN 
SPAIN 
After the need of promulgation of Royal Decree 
1/2015, of July 24, amending law of guarantees and 
rational use of medicines and health products (6), it has 
been set a clear and necessary definition of counterfeit 
medicine. The metioned Act defines counterfeit medicine 
as: “Medicines that are deliberately and fraudulently 
mislabelled with respect to: 
1. º Its identity, including packaging and labeling, 
name or composition in regard to any of its components, 
including excipients and the dosage of those ingredients; 
2. ° its source, including the manufacturer, country of 
manufacturing, country of origin and the holder of the 
marketing authorization; or, 
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3. ° its history, including records and documents in 
relation with the distribution channels used." 
This problem is by no means trivial. The existence of 
counterfeit medicines is not new. There is plenty of 
historical data (7) demonstrating the use of these 
medicines since time immemorial. It is true that this 
problem has lived with human beings from almost its 
origin, but the most significant rise has occurred in the last 
forty years when population started to consume medicines, 
most of time, almost everyday. 
For this important reason, several European institutions 
enacted different guidelines that were transposed into 
Spanish law in relation to our Constitution in the field of 
health protection, preventing the entry of these medicines 
into the legal distribution channel. The European 
Commission noticed the growing dimension of this 
problem and, during the first months of 2008, made an 
inquiry about the key ideas to better protect patients 
against the risk of counterfeit medicines publishing in 
December 2008 a proposal amending Directive 
2001/83/EC as regards the prevention of the entry into the 
legal supply system of medical products which are 
falsified in relation to their identity, history or source. 
The Commission made a proposal to amend 
pharmaceutical legislation (8) against counterfeit 
medicines in order to prevent the spread of these through 
the legal supply system. For this, the Commission 
introduced additional guidelines related to products, in 
particular on safety features for medicines subject to 
prescription; new rules regarding distribution and import 
of medicines and active pharmaceutical ingredients 
(API's); and rules regarding the quality of manufacturing 
and the authenticity of the mentioned API's. 
On the other hand, it should be noted the importance of 
Directive 2011/62/EU (9) amending Directive 2001/83/EC 
(10) that established a European code relating to medical 
products for human use, as regards the prevention of the 
entry of counterfeit medicines  in the legal supply system. 
This new European directive had as its main purpose to 
stop the massive emergence of counterfeit medicines in the 
European Union in both illegal, in most cases, and legal 
(11) channels including a definition of counterfeit 
medicine and making in-depth analysis on rational use of 
medicines and their distribution within the Union 
European in order to prevent the proliferation of 
counterfeit medicines. 
However, we should be aware of the existence of other 
"non-legislative" weapons that enable the eradication of 
this phenomenon at least in Spain and, consequently, on 
many occasions, in the European Union. From our point of 
view, health workforce education is the most essential 
component for health promotion in most constitutions 
worldwide. 
It is desirable to emphasize the importance of health 
workforce education in connection with counterfeit 
medicines. The health workforce education is defined by 
the World Health Organization as "a set of information and 
education activities that encourage people to enjoy good 
health, to know how to attain it, to do everything as 
possible individually and collectively in order to maintain 
health and to ask for help if needed." 
Furthermore, this definition could be extended, from 
our point of view, considering the Spanish legal system, 
specifically to Law 44/2003, of 21 November, on Health 
Profession (12) Planning which highlights the educational 
role that health professionals should have with their 
patients. 
We have abovementioned the existence of several 
initiatives both from a legislative and non-legislative point 
of view used by authorities and health professionals to try 
to partially eradicate the proliferation and development of 
the problem of counterfeit medicines both in legal and 
illegal distribution channels. 
The aim of this work is not to describe in detail the 
methods and initiatives of combating the rapid rise; 
however, we would like to show some of them due to the 
importance they have had in the possible modification of 
both Spanish and EU regulation. 
The first initiative we would like to emphasize is the 
National Strategic Plan 2012-2015 for medicines 
coordinated by the Spanish Medicine Agency's and Health 
Products. This initial strategy was articulated as a response 
from all sectors involved in order to shield the 
pharmaceutical channel against attempts to introduce 
counterfeit medicines. 
After the term of the previous strategy (2008-2011) and 
after the approval of Directive 2011/62/EU, a new overall 
Strategic Plan, with the same principles as the previous 
strategy, was designed; however, this new one raised new 
performances based on the changes in recent years in order 
to strengthen their effectiveness. The main objective is to 
protect the health of patients preventing them from 
consuming counterfeit medicines. 
Secondly, we would like to indicate that group 
IMPACT (The International Medical Product Anti-
Counterfeiting Task Force) published a document entitled 
“Anti- counterfeit Technologies for the Protection of 
Medicines”. This work shows the various technologies 
available to, to the extent possible, try to alleviate the 
proliferation of counterfeit medicines (13). 
Finally, and from a more global perspective, we 
highlight the publication in 2014 of the document entitled 
National Guidelines for Pharmacists by the International 
Pharmaceutical Federation (FIP) in order to combat 
counterfeit medicines and provide member institutions a 
plan to facilitate the development of a national guideline 
for pharmacists on counterfeit medicines (already done, as 
stated above, in Spain both in 2007-2011 and 2011-2015). 
In the first part of the mentioned guideline different 
definitions of counterfeit medicines and their extension to 
counterfeit medical devices are reviewed; and it also 
includes an analysis of the extent of the problem from an 
international perspective. Then, the document provides a 
list of thirty-two medicines most likely to be adulterated, 
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and reviews the consequences for personal and public 
health. Furthermore, this document also provides a tool for 
visual inspection to facilitate the detection of counterfeit 
medicines. 
It is true that the occurrence of such medicines has 
considerably increased in recent years due to the 
emergence of new technologies that allow the 
purchaser/patient buying medicines through telematics 
channels. In many of these cases, the purchaser ignores the 
existing rules on the sale of such products and because 
both the comfort of acquiring them and the anonymity that 
occurs in this purchase, he/she prefers to use this channel 
without being aware that most of the time he/she is buying 
a counterfeit medicine. It is for this reason that European 
health authorities have tried to stop this indiscriminate 
selling enabling pharmacies legally established to sell 
online some medicines that before patients only could buy 
in the pharmacy. 
However, at present the society is fully linked due to 
the rapid expansion of the Internet phenomenon that 
provides users large amounts of information, sometimes 
excessive, and allows the purchase of products through the 
network. 
Consequently, this outrageous commercialism has 
caused the sale of different types of goods, including 
medicines. This fact has led to a regularization of the 
market to try to eradicate criminal acts.  
Moreover, in the field of European Public Health it is 
worth noting the full respect of the European authorities on 
the responsibilities of Member States for the organization 
and delivery of health services, such as pharmaceutical 
services. We must be aware that pharmacies are health 
institutions (private property and public interest) (14) and 
in Spain are distributed following a demographic and 
geographical (15) criterion ensuring access to medicines to 
almost the entire population (16). In Spain dominates the 
so-called "Mediterranean model" pharmacies which 
enables citizens a high degree of accessibility to 
medicines. 
However, given the massive proliferation of illegal sale 
of medicines  (counterfeit and unauthorized) to the public 
through Internet and with the objective of public protection 
and risks' reduction, the Royal Decree 870/2013 was 
approved, regulating the online selling of non-prescription 
medicines (17) to the public and regulating also the Law 
29/2006 of July 26 on sale of medicines for human use 
through websites for later publishing a single text (Royal 
Legislative Decree 1/2015 of 24 July that approves the 
revised text of the law on guarantees and rational use of 
medicines and health products) which encompasses most 
part of the comprehensive regulation on abovementioned  
medicines. 
On the other hand, it should be noted that in Spain the 
sale of medicines are also done by post (18). However, this 
fact is not similar to the one of selling medicines online. 
The Spanish Constitutional Court allowed this type of sale 
(19) under strict conditions. 
BAES says that allowing the sale of prescription 
medicines by post and telematic procedures to specific 
patients, does not mean that it is possible to dispense these 
medicines outside the official circuit and for this reason, 
the Court strengthens the essential role of health 
professional. 
It is clear that the main aim of the promulgation of the 
Royal Decree was to strengthen the telematic channel in 
order to make it safer when dispensing medicines. 
However, we should notice that only, at least in Spain, 
may be online dispensed non-prescription medicines of 
human use following industrial manufacturing. 
As regards online sale of non-prescription medicines, 
Spanish legislation protects the rational use of medicines, 
establishing a series of guarantees to ensure that the supply 
and demand of medicines is done from a health public 
interest facility, as in the case of the pharmacy, and with 
the performance of a skilled professional, both health and 
scientifically, of medicines as pharmacists. 
The second Additional Provision and sole Transitional 
Provision of the mentioned Royal Decree show that 
pharmacies before starting distance selling of non-
prescription medicines for human use manufactured 
industrially through websites (20) must, firstly, have been 
published a common logo on the website, and secondly be 
running the websites of the Spanish Agency for Medicines 
and Health Products and the competent authorities of the 
Autonomous Communities. 
Pharmacies interested in telematics salling shall send 
their notifications to the competent authorities of their 
autonomous region, so that the latter will be able to 
implement their websites. 
In addition, pharmacies should inform about the 
beginning of their telematics activity, data on 
pharmaceutical holder of the pharmacy that offers such a 
service, and the date of the beginning of the activity, web 
address and should describe the procedures for sending the 
patient medication. 
However, pharmacies that plan to provide this service 
must be aware that it is a "virtual" extension thereof. 
Consequently, the pharmacist must perform the legal and 
ethical measures that regulate their professional work in 
the field of medicines dispension. They should also meet a 
number of requirements described below. 
Firstly, as we have showed in the previous parragraphs, 
they can only perform this service, pharmacies which have 
been legally authorized prior notification of such activity 
to the competent authority of the Autonomous Community 
in which it is located. Orders are directly made to the 
pharmacy through the web address given and it can not 
offer or link to self-medication or self-diagnostic tools that 
avoid the obligatory advice of the pharmacist. 
Secondly, dispensing can be only made by a 
pharmacist, prior personalized advice, located in a 
pharmacy legally established and without the involvement 
of intermediaries. 
Thirdly, it may occur that the buyer is located in 
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another Member State of the European Union. In this case, 
the sale must follow the Spanish law, as well as the 
enforceable one in the country of destination. 
On the other hand, it is important to highlight the 
problems that may arise at the time of the medicines 
delivery. The pharmacist in charge of dispensation of 
medicines is the person responsible of this expedition 
which  may only be sent from the pharmacy responsible 
for the dispensation, indicating, among others, data and 
expenses of mailing, and the address. 
It is also important that after delivering the medicine in 
the address where the user has indicated, refunds are not 
permitted unless the medicines have been delivered by 
mistake, do not correspond with the order or have been 
damaged during the transport. 
With regard to means of payment, the web can offer 
different ways according to the needs of the author. These 
means can be: a) credit/debit card; b) bank transfer; c) 
payment gateways; d) cash on delivery payment. 
In addition, we should consider that when dispensing 
non-prescription medicines, the pharmacist is using 
Internet technology. Consequently, he/she must know that 
such mean facilitates the transmission of information and 
transactions but at the same time it is important to know 
that this is a mean that requires the development and use of 
a series of measures to take advantage of all abilities it can 
eventually provide. 
On the one hand, pharmacies should have a technology 
infrastructure (hardware and software) for dispensingnon-
prescription medicines for human use through websites . In 
addition, the infrastructure developed for the website of 
the pharmacy must ensure the availability of services 
offered during the period established for it, as well as an 
adequate level of usability, presenting structured 
information so that it offers easy, intuitive and fast 
navigation. 
The records of purchases and forms exchanged 
between the user and the pharmacy during the purchase 
process should be stored in a secure system that guarantees 
that the information is kept for a minimum period of two 
years (the maximum required by law). 
The information used in dispensing through websites of 
non-prescription medicines for human use is related to the 
user's health. For this reason there must be included 
security measures described in Royal Decree 1720/2007 
(21), of 21 December, which approves the Regulation 
implementing Organic Law 15/1999, of 13 December (22), 
on the Protection of Personal Data.  It is also 
recommended conducting a daily backup of the system and 
of the users and purchases data recorded on the web. Thus, 
the legal compliance of service record will be guaranteed 
for at least two years against possible failures. 
All these requirements are not a simple list of 
exigencies to enable the performance of these services. It 
is an effective and safe way to ensure users/patients the 
accessibility to non-prescription medicines for human use 
through Internet and to regulate exhaustively this sale to 
deal with the problem of illegal purchase of medicines 
through telematics channels that in many cases are the 
entry mechanism of the reported counterfeit medicines.  
3. CONCLUSION 
The counterfeiting of medicines is a major problem 
worldwide, affecting in varying degrees to all countries. 
Adequate legislation and clear definition concerning 
counterfeit medicine is necessary. Today we need a 
harmonized at international level in terms of definition of 
counterfeit medicine, although various attempts to carry 
out coordination at the local level to be necessary to ensure 
adequate regulation, control and research. There are 
several initiatives at both international and European 
Union level to eradicate counterfeit drugs. In this paper we 
have analyzed European standards and the various national 
and international strategic plans that have been established 
to try to resolve this emerging problem. 
In our view, it is necessary to provide more 
information to patients and healthcare professionals about 
the risk involved in the use of these drugs. It is essential to 
raise awareness of irrigation there to buy drugs by 
telematics ways, since there is a possibility that they are 
false. 
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